Cutaneous Dermatomyositis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2025-10-08
Clinical Trial Update: Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis [Phase 2]
A Phase 2 clinical trial evaluating topical ruxolitinib cream for refractory cutaneous dermatomyositis is currently recruiting.